| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.24 | 2e-07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.25 | 4e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 5e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.2 | 0.0003 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0006 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.17 | 0.003 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.007 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |